GlassScriptPhysician profile
Christopher B Hemphill
NPI 1053316232
$401.18
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $116 · 2022: $24.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $143.45 | 2019-2020 | |
| Pfizer INC. | $39.78 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.77 | 2020 | |
| Philips North America LLC | $34.03 | 2019 | |
| Abbott Laboratories | $24.25 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.06 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.78 | 2019 | |
| Amgen INC. | $15.16 | 2020 | |
| Amarin Pharma, INC. | $13.94 | 2020 | |
| Glaxosmithkline, LLC. | $13.18 | 2020 | |
| Novo Nordisk INC | $12.92 | 2019 | |
| Lilly USA, LLC | $11.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.89 | 2019 | |
| Abbvie INC. | $11.04 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hemphill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.